Trial Profile
An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Methotrexate; Methotrexate; Methotrexate
- Indications Plaque psoriasis
- Focus Adverse reactions
- Acronyms TRANSIT
- Sponsors Janssen-Cilag
- 07 Nov 2012 Quality of life outcomes presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
- 28 Sep 2012 Results were presented at the 21st European Academy of Dermatology and Venereology (EADV) congress in late September 2012.
- 16 Nov 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.